Page 43 - Demo

Panitumumab and chemoradiation for inoperable pancreatic cancer41219. Toulany M, Kasten-Pisula U, Brammer I, Wang S, Chen J, Dittmann K, et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase- AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 2006;12:4119%u201326. 20. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008; 14:5142%u20139. 21. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007;25:1134%u201343. 22. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemothera- py-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658%u201364. 23. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989; 45:925%u201337. 24. LoRusso PM, Boerner SA, Seymour L. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics. Clin Cancer Res 2010;16:1710%u20138. 25. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http://ctep.cancer.gov/ protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. 26. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guide- line (version 1.1). Eur J Cancer 2009;45:228%u201347. 27. De Lange SM, van Groeningen CJ, Meijer OWM, Cuesta MA, Langendijk JA, van Riel JMGH, et al. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 2002;38:1212%u20137. 28. Morak MJM, Richel DJ, van Eijck CHJ, Nuyttens JJME, van der Gaast A, Vervenne WL, et al. Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Radiother Oncol 2011;98:261%u20134. 29. Van der Horst A, Wognum S, Davila Fajardo R, de Jong R, van Hooft JE, Fockens P, et al. Interfractional position variation of pancreatic tumors quantified using intratumoral fiducial markers and daily cone beam computed tomography. Int J Radiat Oncol Biol Phys 2013;87:202%u20138. 30. Lens E, van der Horst A, Kroon PS, van Hooft JE, Davila Fajardo R, Fockens P, et al. Differences in respiratory-induced pancreatic tumor motion between 4D treatment planning CT and daily cone beam CT, measured using intratumoral fiducials. Acta Oncol Stockh Swed 2014;53:1257%u201364. 31. Davila Fajardo R, Lekkerkerker SJ, van der Horst A, Lens E, Bergman JJ, Fockens P, et al. EUS-guided fiducial markers placement with a 22-gauge needle for image-guided radiation therapy in pancreatic cancer. Gastro- intest Endosc 2014;79:851%u20135. 32. Kim GP, Foster NR, Haddock MG, Bollinger JW, Dakhil SR, Behrens RJ, et al. North Central Cancer Treatment Group phase II study of panitumu- mab (Pmab), chemotherapy, and external beam radiation (Chemo-RT) in patients with locally advanced (LA) pancreatic cancer. J Clin Oncol [Inter- net] 2012;30 [cited 2014 Jul 10]. Available from: http://meetinglibrary. asco.org/content/88540-115 33. Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, et al. Phase II trial of cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study. Transl Oncol 2014;7:55%u201364. 34. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pat- tern of disease progression. J Clin Oncol 2011;29:3037%u201343. 35. Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation fol- lowed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. J Clin Oncol 2009;27:4096%u2013102. 36. Chiorean EG, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, et al. Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2014;89:284%u201391. 37. Czito BG, Willett C, Kennedy-Newton P, Tyler DS, Hurwitz H, Uronis HE. A phase I study of erlotinib, bevacizumab, and external beam radiation therapy (RT) for patients with localized pancreatic carcinoma (PC). J Clin Oncol [Internet] 2011;29: 2011 (suppl 4; abstr 281) [cited 2015 Feb 12]. Available from: http://meetinglibrary.asco.org/content/71241-103